On this page
The pipeline drugs drawing the most attention are retatrutide (a triple-hormone agonist) and CagriSema (an amylin-plus-semaglutide combination), and both are still investigational. One former pipeline drug just crossed the line: orforglipron, the first oral small-molecule GLP-1 pill, was FDA-approved in April 2026 as Foundayo. The drugs still in trials, you can't get by prescription yet.
Semaglutide and tirzepatide changed what weight-loss medicine can do, and the companies behind them aren't standing still. A handful of next-wave drugs are working through trials right now, and a few have posted numbers that beat anything on the market today. It's worth knowing what's real, what's still being studied, and why "coming soon" is doing a lot of work in some of the marketing you'll see.
Here's the honest frame before we get into specifics. Investigational means a drug is still being tested for safety and effectiveness and has not been approved for sale. Promising phase 2 data has fallen apart in phase 3 before. So treat the figures below as early signals, not finished answers.
Retatrutide, the triple agonist
Retatrutide is the one most people have heard about. It's an Eli Lilly drug that hits three receptors at once: GLP-1 and GIP (the same two tirzepatide targets) plus glucagon, which nudges the body to burn more energy. In a phase 2 trial published in the New England Journal of Medicine in 2023, adults on the highest dose lost a least-squares mean of 24.2% of their body weight at 48 weeks, compared with about 2% on placebo. That's the largest average loss any drug in this class has reported so far.
A few caveats keep that number in perspective. Phase 2 trials are small and short, and they're designed to find a dose, not to prove a drug works at scale. The larger phase 3 program (called TRIUMPH) is still running. Until those results are in and the FDA has reviewed them, retatrutide is investigational. The 24% figure is a reason to pay attention, not a promise you can fill at a pharmacy.
Orforglipron and oral options
This is the part of the pipeline that just became real. Most GLP-1 drugs are peptides, which is why they're injected and, in pill form like Rybelsus, come with finicky fasting rules. Orforglipron is different. It's a once-daily small-molecule GLP-1 pill from Lilly that you can take any time of day, with no food-or-water timing restrictions. The FDA approved it in April 2026 under the brand name Foundayo, making it the first oral small-molecule GLP-1 cleared for weight loss. In the phase 3 ATTAIN-1 trial behind that approval, reported in the New England Journal of Medicine in 2025, the top dose produced about 11% mean weight loss at 72 weeks. That trails the best injectables, but it lands in real territory for a pill, and a daily tablet sidesteps the supply bottlenecks that have dogged the shots.
An oral semaglutide at a weight-loss dose, the so-called Wegovy pill, was cleared a few months earlier, at the end of 2025. Pills are now a genuine option rather than a someday promise. For the full comparison of tablets against shots, our guide on oral GLP-1 medications walks through where each one fits.
CagriSema and other combinations
Novo Nordisk's answer pairs semaglutide with cagrilintide, an analog of the gut hormone amylin that works on appetite through a separate pathway. The idea is that two mechanisms together outperform either alone. In the REDEFINE 1 trial published in the New England Journal of Medicine in 2025, CagriSema produced a mean weight reduction of about 20% at week 68 in people with overweight or obesity. That's a strong result by any normal standard. It also landed below the roughly 25% some analysts had penciled in, a useful reminder that expectations and data don't always line up.
CagriSema points to where the field is heading: amylin-based drugs, combination products, and dosing that's less frequent or oral. Survodutide, a GLP-1 and glucagon drug from Boehringer Ingelheim and Zealand Pharma, is another combination working through trials. None of these is approved yet, and each still has to clear phase 3 and regulators.
The pattern I watch for is whether the big phase 2 number holds up in a bigger, longer phase 3 study. That's where a lot of promising drugs come back to earth.
— John Venzor, DO
What this means for you
If you're weighing your options today, the practical takeaway is simple. The pipeline is genuinely active. Orforglipron already crossed into approval, and a few others like retatrutide and CagriSema may end up stronger than what we have now. But for the drugs still in trials, "may" and "investigational" are load-bearing words. Approval timelines slip, and a drug that isn't approved isn't something a clinician can prescribe.
What you can act on right now is the medicine that's already proven and available:
- Tirzepatide (Mounjaro, Zepbound). The most effective approved option, with average loss past 20% in its trials. See our tirzepatide guide.
- Semaglutide (Ozempic, Wegovy). The most widely used, with about 15% average loss.
- Orforglipron (Foundayo). The newest option and the first GLP-1 pill of its kind, approved in April 2026.
- Compounded versions of semaglutide and tirzepatide, which lower the cost. Our compounded-vs-brand guide lays out the trade-offs.
One more thing, because the hype around the pipeline has a downside.
Investigational drugs like retatrutide and CagriSema aren't available by prescription yet, which means any website selling "next-gen," "research," or "for research only" peptides is operating outside the rules. These products skip the testing and quality controls that protect you, and what's in the vial may not match the label. If a seller offers an unapproved drug without a clinician, walk away.
The smarter move is to start with a treatment that's been tested and approved, work with a clinician who monitors how you respond, and switch later if something better clears the bar. The next generation will get here on its own schedule.